Clinical Trials Browser

Terminated × OTHER × dalotuzumab × Clear all

NCT00903006 2015-02-02

Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer

Phase 1/2 Terminated

11 enrolled 6 charts

Breast Neoplasms